How can companies adapt their single evidence package at launch into multiple, tailored versions for HTAs that vary across different countries and regions?
Cristiana Toader
Advertisement
Cristiana Toader is Manager at Executive Insight.
Articles by Cristiana Toader
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Libtayo for Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma
2
The Situation We Faced: The Development and Commercialization of MariTide
3
Most Favored Nation Order: Legal Battles, Market Shifts, and the Future of Drug Pricing Reform
4
Novo Nordisk Enters $4.7 Billion Definitive Agreement with Akero Therapeutics
5
